Choksi Laboratories Downgraded to Sell Amid Mixed Fundamentals and Technical Signals

Technical Trends Shift to Mildly Bullish but Mixed Signals Persist

The downgrade was primarily triggered by a change in the technical grade, which moved from bullish to mildly bullish. On a weekly basis, key indicators such as the MACD and KST remain bullish, supporting some positive momentum. The Moving Averages on a daily scale also continue to signal bullishness, while Bollinger Bands on both weekly and monthly charts suggest mild bullishness.

However, the monthly RSI indicator has turned bearish, and the Dow Theory assessment on a weekly basis is mildly bearish, indicating some underlying weakness. The monthly KST is mildly bearish as well, and the monthly Dow Theory shows no clear trend. These mixed technical signals suggest that while short-term momentum exists, longer-term technical strength is uncertain, contributing to the cautious downgrade.

Choksi Laboratories’ stock price closed at ₹181.20 on 2 Oct 2026, down 1.47% from the previous close of ₹183.90. The stock has traded within a 52-week range of ₹81.85 to ₹216.95, reflecting significant volatility. Recent price action shows a weekly decline of 8.94%, underperforming the Sensex’s 2.27% fall over the same period, although the stock has outperformed the benchmark over longer horizons.

Valuation Grade Upgraded to Very Attractive Despite High PE

In contrast to the technical downgrade, Choksi Laboratories’ valuation grade has improved from attractive to very attractive. The company’s price-to-earnings (PE) ratio stands at 66.3, which is high in absolute terms but comparatively reasonable within its peer group, many of whom trade at even higher multiples. For instance, Gujarat Kidney trades at a PE of 97.17, and Aashka Hospitals at 87.52, both rated very expensive.

Other valuation metrics reinforce this positive view: the enterprise value to EBITDA ratio is 12.53, and the EV to capital employed ratio is a low 2.79, indicating efficient use of capital relative to enterprise value. The PEG ratio of 2.49 suggests moderate growth expectations relative to earnings, while the return on capital employed (ROCE) is 8.95% and return on equity (ROE) is 7.43%, both modest but stable.

This valuation improvement is supported by the stock’s strong relative performance over the medium term. Year-to-date, Choksi Laboratories has delivered a 40.25% return, significantly outperforming the Sensex’s negative 15.62% return. Over three and five years, the stock has generated exceptional returns of 204.79% and 752.71% respectively, dwarfing the Sensex’s 9.24% and 22.37% gains over the same periods.

Flat Financial Trend and Weak Long-Term Fundamentals

Despite the attractive valuation and relative price strength, the company’s financial trend remains flat, particularly in the recent quarter Q1 FY26-27. Net sales have grown at a modest annual rate of 12.18% over the past five years, which is below expectations for a healthcare services firm in a growth phase. Profit growth has been more encouraging, with a 26.7% increase over the past year, but this has not translated into a stronger overall financial trend.

Long-term fundamental strength is weak, as evidenced by an average ROCE of 8.64%, which is barely adequate to cover the cost of capital. The company’s ability to service debt is also concerning, with an average EBIT to interest ratio of just 1.68, signalling limited buffer to meet interest obligations. Cash and cash equivalents are at a low ₹0.21 crore, and the debtors turnover ratio is at a five-year low of 3.12 times, indicating potential issues in working capital management.

These factors weigh heavily on the quality assessment of the company, which remains poor despite some positive valuation signals. The downgrade to Sell reflects these fundamental concerns, as the company’s financial health and growth prospects do not justify a more optimistic rating at this time.

Institutional Investor Interest and Market Position

On a positive note, institutional investors have increased their stake in Choksi Laboratories by 0.99% over the previous quarter, now collectively holding 7.02% of the company. This increased participation suggests that more sophisticated investors see some value or potential in the stock, possibly due to its attractive valuation and relative outperformance over the medium term.

However, as a micro-cap stock in the healthcare services sector, Choksi Laboratories faces challenges related to scale, liquidity, and market volatility. Its current Mojo Score of 47.0 and Mojo Grade of Sell reflect these risks, signalling that investors should approach with caution despite pockets of opportunity.

Conclusion: A Cautious Stance Amid Contrasting Signals

The downgrade of Choksi Laboratories Ltd from Hold to Sell encapsulates the complex reality facing many micro-cap healthcare stocks. While valuation metrics have improved significantly, rendering the stock very attractive relative to peers, the company’s weak long-term fundamentals and mixed technical indicators temper enthusiasm.

Investors should weigh the company’s strong relative returns over the past three to five years and its improved valuation against the flat recent financial performance, weak debt servicing capacity, and uncertain technical outlook. The increased institutional interest is a positive sign but does not fully offset the risks inherent in the company’s financial and operational profile.

For those considering exposure to Choksi Laboratories, a cautious approach is warranted, with close monitoring of upcoming quarterly results and technical developments. The current Sell rating reflects a prudent view that the risks outweigh the rewards at this juncture, despite pockets of value and momentum.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →